Tag: CYTX

Blue Horseshoe Stocks: ABIO Recap & More

ARCA BioPharma, Inc. ABIO

Our top performer from yesterday’s report was most assuredly ABIO. We tagged this play after noticing that it had announced being granted orphan drug status by the FDA for “rNAPc2” as a potential treatment of viral hemorrhagic fever post-exposure to the Ebola virus.

Fresh FDA-related plays can often provide a healthy move to take advantage of, and that’s just what we got from ABIO, The stock traded in a range from .82-1.03, an intraday increase of 25% on nearly ten times the 3-month average volume.

Our long-time readers might recall our coverage of this stock last year in December, which sort of got lost in the shuffle that was the hysteria created by the “Green Rush”. We tracked the stock from the low 1.40’s to over 2.20 over a period of a few weeks, so it will be interesting to see if history continues to repeat itself with ABIO, especially with the stock coming off of it 52-week low on Tuesday.

CYREN Ltd. CYRN

We also wanted to acknowledge the early morning move made by another of the stocks we mentioned in yesterday’s newsletter, CYRN. It bolted out of the gate, quickly running from 2.22 to 2.67, a 20% spike within the first 15 minutes of the session.

The stock got hammered into the close quite a bit, so we’ll be open to the possibility of seeing some bounce action, provided it can hold support at or above the 50DMA of 1.75.

Office Depot, Inc. ODP

ODP is in the midst of making a big move on the heels of large activist investor Starboard Value taking up a position which equates to 6% of ODP’s total shares. It also upped its stake in Staples to 10% fueling speculation that it could create pressure for the two office supply giants to merge. It will definitely be a story that we’ll be interested to follow moving forward.

Extended Watchlist:
GPT, RGDX, CYTX, DRD

Blue Horseshoe Stocks: LXRP News Update & FDA-Related Plays

Lexaria Corp. LXRP

Following our initial report on LXRP yesterday, the stock had a productive session as it traded in a range from .095 to a high of .108, an intraday gain of 14% on roughly 2.5X the monthly average volume. It closed at .102 holding more than half of the day’s gains, which is generally a good sign.

We promised to relay any further updates regarding the current status of LXRP, and sure enough the company published a fresh PR this morning containing another major development. It relates to the sale of Lexaria’s domestic oil assets, which we mentioned in yesterday’s report, becoming final with all funds received. It provides LXRP with a cash infusion of $1.4M which will facilitate a clearing of all debt currently on the books, as well as advance the company’s plans to release a CBD-infused tea (infusion method is patent pending) via a new online sales portal. With the rate at which LXRP has been executing its strategies, we expect to hear about the opening of that website any day now.

KELOWNA, BC / ACCESSWIRE / December 10, 2014 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratulates the new owners for having purchased a fine asset. >> FULL PR

FDA-Related News

We caught a couple of FDA news plays on this morning’s scan that we’ll want to keep an eye on:

ARCA BioPharma, Inc. ABIO has reported that the FDA “has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.” >> VIEW PR

Cytori Therapeutics, Inc. CYTX announced that the FDA granted approval “for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.” >> VIEW PR

Extended Watchlist:
 CYRN, SYMX, SNSS

Blue Horseshoe Stocks: Pot Stocks Take Off, Updates & More

Marijuana Sector Heating Up

We sincerely hope at least a few of our readers were able to take advantage of our perfectly-timed “Marijuana Sector Reminder” in yesterday’s morning report. Therein we reiterated an earlier warning we issued that the approaching voting season, increased judicial inquiry, and growing acceptance of cannabis could lead to another sectorwide surge.

We went as far as naming a few of our past winners we felt were prime candidates to bring us further opportunities: MJNA, CBIS, HEMP, GRNH, TRTC & ERBB, and we couldn’t have gone wrong with any of them. In a stroke of extreme good fortune, every single one of these plays was sent on a ride yesterday!

MJNA – Range: .155-.18 – Max Gain: 16%

CBIS – Range: .061-.074 – Max Gain: 21%

HEMP – Range: .036-.057 – Max Gain: 58%

GRNH – Range: .134-.225 – Max Gain: 68%

TRTC – Range: .321-.372 – Max Gain: 16%

ERBB – Range: .0167-.0209- Max Gain: 25%

CUMULATIVE TOTAL: +204%

We’re going to continue to keep an eye on the sector as volatility ramps up. We expect to see more good moves from these and other marijuana stocks over the next several weeks, so be sure to stay tuned to our coverage as we follow along with yet another exciting cannabis trend.

Pazoo, Inc. PZOO

PZOO continued to fare well on Wednesday, making positive strides in both PPS and volume each day this week since our initial report on Monday.

The stock began at a low of .0225 the first day, broke through its 50DMA trading as high as .031 on Tuesday, and yesterday it pushed its limits even further to .037. That marks a three-day overall increase of 64%

We were pleased to be updated yesterday morning on the build-out status of the marijuana testing facilities being set up by MA & Associates, in which PZOO is a 40% stakeholder. >>VIEW PR

Today, it announced the 3rd installment of Pazoo Radio as well, so in addition to a positive progression on the chart, the company has a lot going on in all other aspects as well, which is why we intend to stay hot on the trail of PZOO for the foreseeable future.

Image Sensing Systems, Inc. ISNS

On Tuesday, we tagged this play stating that we wanted to “reassign ISNS a spot on our speculative watchlist.” as a result of the activity we were seeing as it came off of a bottom. At the time, we observed a low of 2.31, and yesterday, the stock attained a high of 3.46.

That marks a 50% overnight turnaround, so big cheers go out to anyone who hopped on ISNS with us!

Extended Watchlist:
VSR(News), CYTX(FDA approval), JAKK, INFN, IGC, DRD

Ecologic Transportation, Inc. | EGCT & Extended Watchlist

Ecologic Transportation Inc. EGCT

We’d like to welcome all of our new subscribers today. Those of you who have been with us for awhile, know that we have covered EGCT consistently for a good long while now. We first added it to our radar back on July 16th, and have no plans to cease our coverage any time soon.

This stock has given us tons of opportunities along the way. When we first began covering EGCT, it was trading as low as .30, subsequently running as high as .48. Next it dipped to .22 before turning up and surging back to .46. Again the stock pulled back, this time to .21, before reversing once again and touching .40. This week, EGCT has maintained a higher level of support, not trading any lower than .35, which is now acting as the new support level. Below .35, we seem to have support sitting at .30, and .25 as well.

We have prepared a detailed annotated chart this morning to illustrate some of the key technical points of EGCT. Looking at the chart, you can see that the stock has traded in a tight channel, achieving higher highs and higher lows, and offering savvy traders the chance to take advantage of large percentage gains from the bounces it has seen. In the time of our coverage, there has been the opportunity to lock in over 260% in cumulative gains. We’ve identified the key levels of resistance to be .40 and .45, a move past which point could send us into blue sky breakout mode.

It has been quite the rollercoaster thus far, but we feel that the ride is a long way from over. In fact, it has yet to even truly begin. The impending acquisition of ACE Rent A Car is the main element in what we feel should be an exciting future for EGCT. Once the recently announced financing is secured for said acquisition, things should really get interesting.

If you didn’t catch the special report we put out on EGCT a couple of weeks back, we strongly encourage you to do so now:

EGCT Special Report

____
Extended Watchlist:

RFMK, BBDA, BLVT, CEII, ASTX, CYTX, TPI, BYFC, WSGI (Potential Bottom),  

Get Our FREE Daily Reports!

SUBSCRIBE